INT82950

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 1999
Last Reported 2011
Negated 2
Speculated 1
Reported most in Body
Documents 36
Total Number 37
Disease Relevance 11.72
Pain Relevance 10.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (Gdnf) extracellular space (Gdnf) extracellular region (Gdnf)
Anatomy Link Frequency
neurons 6
glial cell 3
striatum 2
brain 2
cerebrospinal fluid 1
Gdnf (Mus musculus)
Pain Link Frequency Relevance Heat
bDMF 8 100.00 Very High Very High Very High
Morphine 27 99.82 Very High Very High Very High
Nucleus accumbens 3 99.82 Very High Very High Very High
Nerve growth factor 139 99.72 Very High Very High Very High
nociceptor 35 99.70 Very High Very High Very High
Antinociceptive 1 99.64 Very High Very High Very High
cytokine 26 99.52 Very High Very High Very High
chemokine 4 99.52 Very High Very High Very High
Spinal cord 47 99.44 Very High Very High Very High
antidepressant 37 99.44 Very High Very High Very High
Disease Link Frequency Relevance Heat
Parkinson's Disease 785 99.62 Very High Very High Very High
Toxicity 157 99.62 Very High Very High Very High
Motor Neuron Diseases 396 99.44 Very High Very High Very High
Ganglion Cysts 70 98.56 Very High Very High Very High
Targeted Disruption 177 98.50 Very High Very High Very High
Pain 7 97.44 Very High Very High Very High
Injury 4 95.08 Very High Very High Very High
INFLAMMATION 65 94.56 High High
Disease 372 94.28 High High
Nervous System Injury 4 91.48 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Upon treatment of astrocytes with fluoxetine or desipramine for 48 h, the expression level of GDNF mRNA was higher in cells treated with each antidepressant than that in control cells (Fig. 1B), thereby indicating that these antidepressants were effective at least in inducing GDNF in the astrocytes.
Positive_regulation (inducing) of GDNF in astrocytes associated with antidepressant, desipramine and fluoxetine
1) Confidence 0.51 Published 2007 Journal Mol Pain Section Body Doc Link PMC1904438 Disease Relevance 0.11 Pain Relevance 0.58
Function-blocking studies with BDNF specific antibodies in vitro or cultures of BDNF-deficient sensory neurons suggest that BDNF acts in an autocrine/paracrine way to promote the early postnatal survival of nociceptors that are also responsive to NGF and GDNF.
Positive_regulation (responsive) of GDNF in nociceptors associated with nociceptor
2) Confidence 0.49 Published 2010 Journal Dev. Biol. Section Abstract Doc Link 20067784 Disease Relevance 0.38 Pain Relevance 0.45
Leu-Ile inhibits METH- or MOR-induced place preference and sensitization by attenuating the METH- or MOR-induced increase in extracellular dopamine levels in the nucleus accumbens via the induction of GDNF and TNF-alpha expression.
Positive_regulation (induction) of GDNF in nucleus accumbens associated with nucleus accumbens, dopamine and morphine
3) Confidence 0.48 Published 2007 Journal J. Pharmacol. Sci. Section Abstract Doc Link 17538232 Disease Relevance 0.69 Pain Relevance 0.96
A corresponding increase in mRNA for the artemin coreceptor GFRalpha3 (for GDNF family receptor alpha) was seen in DRG, and GFRalpha3 immunoreactivity was widely colocalized with TRPV1 in epidermal afferents.
Positive_regulation (increase) of GDNF in DRG associated with dorsal root ganglion
4) Confidence 0.47 Published 2006 Journal J. Neurosci. Section Abstract Doc Link 16914685 Disease Relevance 0.77 Pain Relevance 1.38
It has been shown that IB(4)-positive neurons depend on glial-derived neurotrophic factor (GDNF), whereas IB(4)-negative neurons depend on NGF for survival during postnatal development (Molliver et al., 1997).
Positive_regulation (depend) of glial-derived neurotrophic factor in neurons
5) Confidence 0.47 Published 1999 Journal J. Neurosci. Section Abstract Doc Link 10414978 Disease Relevance 0.13 Pain Relevance 0.40
We decided to examine whether doses of 0.25 or 3 mg/kg of LY379268, which
                   enhanced GDNF levels in the striatum, were protective against nigro-striatal
                   damage in mice treated with MPTP. 
Positive_regulation (enhanced) of GDNF in striatum associated with parkinson's disease
6) Confidence 0.47 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0.49 Pain Relevance 0.04
Double labelling analysis by
                   combined in situ hybridization and immunohistochemistry (GDNF
                   mRNA+NeuN or GFAP) showed that GDNF is expressed in neurons (Fig. 5A) and treatment with
                   LY379268 (0.25 mg/kg, i.p., 3 h) selectively increased GDNF mRNA levels in
                   neurons (not shown). 
Positive_regulation (increased) of GDNF in neurons
7) Confidence 0.47 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0.25 Pain Relevance 0.03
is required for the ability of GDNF to rescue
               target-derived sympathetic spinal cord neurons [41], and antibodies
               neutralizing the three isoforms of TGF-? 
Positive_regulation (required) of GDNF in spinal cord neurons associated with spinal cord
8) Confidence 0.47 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0.08 Pain Relevance 0.08
A single injection of
                   LY379268 alone enhanced GDNF levels by more than 2 fold after 1 day. 
Positive_regulation (enhanced) of GDNF
9) Confidence 0.47 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0.49 Pain Relevance 0.03
Tyrosine hydroxylase (TH), glial cell line-derived neurotrophic factor (GDNF)
                   and glial fibrillary acidic protein (GFAP) immunostaining
Positive_regulation (derived) of GDNF in glial cell
10) Confidence 0.47 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0 Pain Relevance 0.04
Tyrosine hydroxylase (TH), glial cell line-derived neurotrophic factor (GDNF)
                   and glial fibrillary acidic protein (GFAP) immunostaining
Positive_regulation (neurotrophic) of GDNF in glial cell
11) Confidence 0.47 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0 Pain Relevance 0.04
The finding that reduced GDNF level alters the effects of morphine on striatal dopamine and our previous findings of elevated extracellular striatal dopamine concentrations and FosB/DeltaFosB expression in the GDNF+/- mice show the importance of GDNF in the regulation of striatal dopaminergic system.
Positive_regulation (importance) of GDNF associated with dopamine and morphine
12) Confidence 0.44 Published 2006 Journal Synapse Section Abstract Doc Link 16437537 Disease Relevance 0.07 Pain Relevance 0.92
Repeated pre-treatment with Leu-Ile for 9 days potentiated the MOR-induced increase in GDNF levels.
Positive_regulation (increase) of GDNF associated with morphine
13) Confidence 0.43 Published 2007 Journal Behav. Brain Res. Section Abstract Doc Link 17331595 Disease Relevance 0.29 Pain Relevance 1.09
GDNF mRNA levels peaked at 3 h and declined afterwards, whereas GDNF
                   protein levels progressively increased from 24 to 72 h following LY379268
                   injection. 
Positive_regulation (increased) of GDNF
14) Confidence 0.43 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2719807 Disease Relevance 0.38 Pain Relevance 0.23
For example, the orally
               active compound, PYM50028, which elevates striatal levels of GDNF, is protective
               against MPTP toxicity in mice [47], and induction of GDNF is associated with the
               neurorescue action of rasagilin, a drug of current use in the treatment of
               Parkinson's disease [48], [49]. 
Positive_regulation (induction) of GDNF associated with parkinson's disease, toxicity and disease
15) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0.61 Pain Relevance 0.13
Treatment with 0.25 mg/kg LY379268
                   increased GDNF protein levels in both the striatum and cerebral cortex after 72
                   h (Fig. 3A,B). 
Positive_regulation (increased) of GDNF in striatum associated with cerebral cortex
16) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0 Pain Relevance 0.23
The increase in striatal GDNF mRNA levels induced by a single injection of
                   LY379268 peaked after 3 h (Fig.
                       1D) and was prevented by the preferential mGlu2/3 receptor
                   antagonist, LY341495 (1 mg/kg, i.p.), which had no effect on its own (Fig. 1E). 
Positive_regulation (induced) of GDNF associated with antagonist
17) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0 Pain Relevance 0.07
The increase in striatal GDNF mRNA levels induced by a single injection of
                   LY379268 peaked after 3 h (Fig.
                       1D) and was prevented by the preferential mGlu2/3 receptor
                   antagonist, LY341495 (1 mg/kg, i.p.), which had no effect on its own (Fig. 1E). 
Positive_regulation (increase) of GDNF associated with antagonist
18) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0 Pain Relevance 0.07
Activation of mGlu3 receptors enhances GDNF levels in cultured striatal
                   neurons (but not in astrocytes) via the activation of the MAP kinase and the
                   phosphatidylinositol-3-kinase pathways
Positive_regulation (Activation) of GDNF in neurons
19) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0.30 Pain Relevance 0
A combination of in vivo and in vitro
                   experiments clearly showed that the source of the GDNF responsive to mGlu3
                   receptor activation was exclusively neuronal. 
Positive_regulation (activation) of GDNF in neuronal
20) Confidence 0.41 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719807 Disease Relevance 0.17 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox